Gu YQ, Zhou X, Yao LH, Wang Q, Zhou CN, Liu ZD. Relationship between serum neutrophil gelatinase-associated lipocalin levels and cognitive impairment, anxiety, and depressive symptoms in acute ischemic stroke. World J Psychiatry 2024; 14(10): 1467-1473 [PMID: 39474380 DOI: 10.5498/wjp.v14.i10.1467]
Corresponding Author of This Article
You-Quan Gu, MM, Chief Physician, Department of Neurology, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. guyq@lzu.edu.cn
Research Domain of This Article
Psychiatry
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Oct 19, 2024; 14(10): 1467-1473 Published online Oct 19, 2024. doi: 10.5498/wjp.v14.i10.1467
Table 1 Baseline characteristics of the study population stratified by the presence or absence of cognitive impairment, anxiety, and depressive symptoms
Characteristic
Cognitive impairment
P value
Anxiety
P value
Depressive symptoms
P value
Yes (n = 52)
No (n = 98)
Yes (n = 42)
No (n = 108)
Yes (n = 48)
No (n = 102)
Age, year, mean ± SD
68.3 ± 9.5
63.8 ± 10.3
0.010
66.9 ± 9.8
64.8 ± 10.3
0.261
67.5 ± 9.6
64.4 ± 10.3
0.083
Male, n (%)
28 (53.8)
59 (60.2)
0.448
22 (52.4)
65 (60.2)
0.379
25 (52.1)
62 (60.8)
0.312
BMI, kg/m2, mean ± SD
24.8 ± 3.2
24.3 ± 3.1
0.356
24.5 ± 3.3
24.5 ± 3.1
0.980
24.6 ± 3.2
24.4 ± 3.1
0.720
Smoking, n (%)
18 (34.6)
30 (30.6)
0.614
15 (35.7)
33 (30.6)
0.540
17 (35.4)
31 (30.4)
0.534
Hypertension, n (%)
37 (71.2)
61 (62.2)
0.273
29 (69.0)
69 (63.9)
0.548
33 (68.8)
65 (63.7)
0.544
Diabetes, n (%)
19 (36.5)
28 (28.6)
0.311
15 (35.7)
32 (29.6)
0.472
18 (37.5)
29 (28.4)
0.262
Dyslipidemia, n (%)
28 (53.8)
46 (46.9)
0.415
22 (52.4)
52 (48.1)
0.639
25 (52.1)
49 (48.0)
0.637
Previous stroke, n (%)
10 (19.2)
14 (14.3)
0.417
8 (19.0)
16 (14.8)
0.522
9 (18.8)
15 (14.7)
0.523
NIHSS score at admission, median (interquartile range)
8 (5-12)
5 (3-9)
0.001
7 (4-11)
6 (3-9)
0.118
8 (4-12)
5 (3-9)
0.007
Table 2 Serum neutrophil gelatinase-associated lipocalin levels at admission in patients with and without cognitive impairment, anxiety, and depressive symptoms
Neuropsychiatric complication
Serum NGAL levels (ng/mL)
P value
Yes
No
Cognitive impairment, median (interquartile range)
5.6 (4.2-7.1)
3.2 (2.4-4.3)
< 0.001
Anxiety, median (interquartile range)
5.1 (3.8-6.6)
3.5 (2.6-4.7)
0.002
Depressive symptoms, median (interquartile range)
5.4 (4.0-6.9)
3.3 (2.5-4.5)
< 0.001
Table 3 Multivariate logistic regression analysis of the association between serum neutrophil gelatinase-associated lipocalin levels and neuropsychiatric comorbidities
Outcome
Odds ratio (95%CI)
P value
Cognitive impairment
1.42 (1.18-1.71)
< 0.001
Anxiety
1.28 (1.09-1.51)
0.003
Depressive symptoms
1.39 (1.16-1.67)
< 0.001
Table 4 Discriminative ability of serum neutrophil gelatinase-associated lipocalin levels for predicting cognitive impairment, anxiety, and depressive symptoms using receiver operating characteristic curve analysis
Neuropsychiatric complication
AUC (95%CI)
Optimal cut-off value (ng/mL)
Sensitivity (%)
Specificity (%)
Cognitive impairment
0.78 (0.71-0.85)
4.2
75.0
70.4
Anxiety
0.67 (0.58-0.76)
4.0
66.7
63.0
Depressive symptoms
0.71 (0.63-0.79)
4.1
70.8
65.7
Citation: Gu YQ, Zhou X, Yao LH, Wang Q, Zhou CN, Liu ZD. Relationship between serum neutrophil gelatinase-associated lipocalin levels and cognitive impairment, anxiety, and depressive symptoms in acute ischemic stroke. World J Psychiatry 2024; 14(10): 1467-1473